P2 peptide (Zhongao Biopharmaceutical Technology)

P2 is a preclinical-stage peptide therapeutic developed by Zhongao Biomedical Technology (Guangdong) Co. Ltd. It is designed to target and blockade the Interleukin-10 receptor (IL-10R) and the associated IL-10 signaling pathway. By inhibiting IL-10 signaling, which is typically immunosuppressive in the tumor microenvironment, P2 aims to enhance anti-tumor T-cell responses and improve the efficacy of therapeutic vaccines. Additionally, its ability to modulate immune responses makes it a candidate for the treatment of various autoimmune diseases. As a peptide-based biologic, it represents a targeted approach to immune modulation through the IL-10 axis.